AstraZeneca Plc (AZN) Q4 2023 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2024/02/08/astrazeneca-plc-azn-q4-2023-earnings-call-transcri/?source=iedfolrf0000001
Feb 08, 2024 - AZN earnings call for the period ending December 31, 2023.
0
Astrazeneca (AZN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
https://www.zacks.com/stock/news/2223659/astrazeneca-azn-q4-earnings-how-key-metrics-compare-to-wall-street-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2223659
Feb 08, 2024 - Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
0
Jobless Claims Steady; Mixed Q4 for AZN, HSY and PM
https://www.zacks.com/stock/news/2223512/jobless-claims-steady-mixed-q4-for-azn-hsy-and-pm?cid=CS-ZC-FT-ahead_of_wall_street-2223512
Feb 08, 2024 - We're once again reassured that employment, on a finer week-over-week scale, is not falling off a cliff.
0
Ionis' (IONS) Olezarsen Gets FDA's Orphan Tag for Rare Disease
https://www.zacks.com/stock/news/2227293/ionis-ions-olezarsen-gets-fda-s-orphan-tag-for-rare-disease?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2227293
Feb 16, 2024 - FDA grants orphan drug status to Ionis' (IONS) olezarsen for treating familial chylomicronemia syndrome (FCS). An NDA for olezarsen is expected to be filed this year.
0
Top Stock Reports for Costco, Walt Disney & AstraZeneca
https://www.zacks.com/commentary/2233623/top-stock-reports-for-costco-walt-disney-astrazeneca?cid=CS-ZC-FT-research_daily-2233623
Feb 29, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Costco Wholesale Corporation (COST), The Walt Disney Company (DIS) and AstraZeneca PLC (AZN).
0
Pharma Stock Roundup: NVO's New Obesity Pill Data, RHHBY, AZN's Pipeline Updates
https://www.zacks.com/stock/news/2238322/pharma-stock-roundup-nvo-s-new-obesity-pill-data-rhhby-azn-s-pipeline-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2238322
Mar 08, 2024 - Novo Nordisk???s (NVO) early-stage data on a new weight loss pill, amycretin, shows it can outperform Wegovy. FDA approves J&J???s (JNJ) Rybrevant for first-line use.
0
Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts
https://www.zacks.com/stock/news/2240290/astrazeneca-azn-rises-as-market-takes-a-dip-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2240290
Mar 13, 2024 - Astrazeneca (AZN) reachead $67.58 at the closing of the latest trading day, reflecting a +0.27% change compared to its last close.
0
AstraZeneca (AZN) to Buy Fusion Pharmaceuticals for $2.4B
https://www.zacks.com/stock/news/2243580/astrazeneca-azn-to-buy-fusion-pharmaceuticals-for-2-4b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2243580
Mar 20, 2024 - AstraZeneca (AZN) has offered to acquire Fusion for $21.00 per share in cash plus a contingent value (CV) payment of $3.00 per share.
0
Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts
https://www.zacks.com/stock/news/2246316/astrazeneca-azn-rises-as-market-takes-a-dip-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2246316
Mar 26, 2024 - In the most recent trading session, Astrazeneca (AZN) closed at $66.33, indicating a +0.71% shift from the previous trading day.
0
AstraZeneca's (AZN) Rare Blood Disorder Drug Gets FDA Nod
https://www.zacks.com/stock/news/2249013/astrazeneca-s-azn-rare-blood-disorder-drug-gets-fda-nod?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2249013
Apr 02, 2024 - FDA approves AstraZeneca's (AZN) Voydeya as an add-on to therapy to Ultomiris or Soliris for treating extravascular hemolysis in adult patients with paroxysmal nocturnal hemoglobinuria.
0
Page 1>